Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects

What Was Tested

This randomized controlled trial paper looks at Bradykinin.

In this study, a specific bradykinin-receptor antagonist, icatibant acetate (HOE 140), was used to determine the contribution of bradykinin to the short-term effects of ACE inhibition on blood pressure and plasma renin activity in both normotensive and hypertensive subjects.

Who Took Part

The abstract describes 20 subjects taking part.

PubMed tags the participants as both men and women.

How the Study Was Run

In design terms this was a randomized, single-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Bradykinin and who got the comparison, which limits bias.

In this single-blind Bradykinin study one party knew the assignments and the other did not.

The comparison arm used a placebo, so changes seen with Bradykinin could be set against what happens without it.

The drugs were administered on four separate study days in a single-blind, randomized fashion.

What Was Measured

Topics PubMed links to this paper include Adrenergic beta-Antagonists, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Blood Pressure, Bradykinin, Bradykinin Receptor Antagonists and Captopril.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Bradykinin in 20 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1998 (The New England journal of medicine), a journal based in United States.

More context: the Bradykinin compound page, all human trials.